AI Drug Discovery Platform HelixMind Identifies Potential Rare Disease Drug Molecules: Target to Candidate in Just 12 Days

Full Article

AI pharmaceutical company HelixMind announced on May 15 that its autonomous drug discovery platform successfully identified three candidate drug molecules for Fabry disease. From target confirmation to virtual screening and preliminary activity verification, the entire process took only 12 days.

Fabry disease is a rare inherited lysosomal storage disorder affecting approximately 40,000 patients globally, with existing treatments costing over $200,000 annually. HelixMind co-founder and CEO Sarah Kim said the company chose rare diseases as its AI drug discovery entry point because "rare disease targets are relatively well-defined with less data noise, making them better suited to validate the AI platform's capabilities."

HelixMind's platform integrates three modules: protein structure prediction, molecular docking simulation, and ADMET property prediction. Unlike traditional AI pharmaceutical companies, HelixMind incorporates quantum chemical calculations in the molecular docking stage to more accurately evaluate drug-target binding energies. The company's technical advisor and 2024 Nobel Chemistry laureate David Baker said this hybrid computational approach improved molecular screening accuracy by approximately 40%.

The three candidate molecules are currently undergoing in vitro cell experiment validation. HelixMind plans to submit clinical trial applications by the end of 2028.

However, the "speed race" in AI drug discovery has also raised concerns among some scientists. MIT Chemical Engineering professor Klavs Jensen noted that while shortening the discovery phase is important, the real bottleneck in drug development lies in clinical trials. "Discovering a molecule in 12 days and producing an effective drug in 12 days are completely different things."